

dA-Thiophosphoramidite

5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Adenosine, 3'-[(- thiobenzoylethyl)-(1-pyrrolidinyl)]-thiophosphoramidite, M.W.: 959.7

dC-Thiophosphoramidite


5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Cytidine, 3'-[(- thiobenzoylethyl)-(1-pyrrolidinyl)]-thiophosphoramidite, M.W.: 950.7

dG-Thiophosphoramidite

5'-Dimethoxytrityl-N-isobutyryl-2'-deoxy-Guanosine, 3'-[(- thiobenzoylethyl)-(1-pyrrolidinyl)]-thiophosphoramidite, M.W.: 936.7

T-Thiophosphoramidite

5'-Dimethoxytrityl-2'-deoxy-Thymidine, 3'-[(- thiobenzoylethyl)-(1-pyrrolidinyl)]-thiophosphoramidite, M.W.: 841.6



Description:

Thiophosphoramidites are activated modified nucleotides which effect the substitution of the two internucleotide non-bridging oxygen atoms with sulfur. The result is a nucleic acid analog with an internucleotide phosphorodithioate linkage that is achiral.

Applications:

PS2 analogues have been successfully used as aptamers for a variety of protein targets including activated-protein 1 (AP-1) as well as transcription factor NFkB for which the PS2-ODN demonstrated 150 picomolar Kd with a dissociation time >12 hours. PS2-ODNs demonstrate up to 300 times greater binding affinity for proteins than oligos without PS2 linkages with no loss of their aptamer specificity.

In addition, PS2-ODNs have been investigated as potential antisense compounds and have exhibited the ability to interfere with the expression of erbB-2 mRNA associated with breast cancer; to induce B-cell proliferation and differentiation; and to potently inhibit HIV-1 reverse transcription activity as well as viral replication. The inhibition is dependent upon both the number of dithioate linkages as well as the length of dithioate oligomer analog. A comparative analysis with phosphorothioate equivalents indicates that dithioates are much better inhibitors and are able to inhibit at relatively short oligomer length. Inhibition of HIV-1 reverse transcriptase by dithioate oligodeoxynucleotides appears to be a general phenomenon as use of any of the nucleotide base sequences examined inhibits its activity.

Bottle Sizes

- 100 mole
- 250 mole
- 500 mole
- 1000 mole

Usage parameters on oligo synthesizers:

- Coupling: Double couplings
- Deprotection: no changes needed from standard DNA methods
- Storage: refrigerated, dry
- Stability in solution: 2-3 days
- Concentration on Synthesizer: 0.1 mM

Purification of PS2 oligos

Strong anion exchange liquid chromatography for high resolution analysis and purification at pH 8. The thiocyanate, SCN⁻, as eluting ion can be used for oligos containing a high percentage of phosphorodithioate linkages.

● Patent Reference:

U.S. Patent Number: 5,218,088 "Process for Preparing Dithiophosphate Oligonucleotide Analogs Via Nucleoside Thiophosphoramidite Intermediates"

Selected Literature References:

1. Ferguson, M.R., Rojo, D.R., Somasunderam, A., Thiviyanathan, V., Ridley, B.D., Yang, X. and Gorenstein, D.G. (2006) Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. *Biochem Biophys Res Commun*.
2. Yang, X., Wang, H., Beasley, D., Volk, D., Zhao, X., Luxon, B., Lomas, L., Herzog, N., Aronson, J., Barrett, A. et al. (2006) Selection of Thioaptamers for Diagnostics and Therapeutics. *Annals of the New York Academy of Sciences*, 1082, 116-119.
3. Wang, H., Yang, X., Bowick, G.C., Herzog, N.K., Luxon, B.A., Lomas, L.O. and Gorenstein, D.G. (2006) Identification of proteins bound to a thioaptamer probe on a proteomics array. *Biochem Biophys Res Commun*, 347, 586-593.
4. Volk, D.E., Yang, X., Fennewald, S.M., King, D.J., Bassett, S.E., Venkitachalam, S., Herzog, N., Luxon, B.A. and Gorenstein, D.G. (2002) Solution structure and design of dithiophosphate backbone aptamers targeting transcription factor NF-kappaB. *Bioorg Chem*, 30, 396-419.
5. Yang, X., Bassett, S.E., Li, X., Luxon, B.A., Herzog, N.K., Shope, R.E., Aronson, J., Prow, T.W., Leary, J.F., Kirby, R. et al. (2002) Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. *Nucleic Acids Res*, 30, e132.
6. Yang, X., Hodge, R.P., Luxon, B.A., Shope, R. and Gorenstein, D.G. (2002) Separation of synthetic oligonucleotide dithioates from monothiophosphate impurities by anion-exchange chromatography on a mono-q column. *Anal Biochem*, 306, 92-99.
9. Farschtschi, N. and Gorenstein, D.G. (1988) Preparation of a deoxynucleoside thiophosphoramidite intermediate in the synthesis of nucleoside Phosphorodithioates. *Tetrahedron Letts*, 29, 6843-6846.
10. Volk, D.E., Power, T.D., Gorenstein, D.G. and Luxon, B.A. (2002) An ab initio study of phosphorothioate and phosphorodithioate interactions with sodium cation. *Tetrahedron Lett*, 43, 4443-4447.
11. Okruszek, A., Olesiak, M., Krajewska, D. and Stec, W.J. (1997) Efficient One-Pot Synthesis of 2'-Deoxyribonucleoside 3'-O- and 5'-O-Phosphorodithioates. *J Org Chem*, 62, 2269-2272.
12. DeLong, R.K., Nolting, A., Fisher, M., Chen, Q., Wickstrom, E., Kligshiteyn, M., Demirdji, S., Caruthers, M. and Juliano, R.L. (1997) Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. *Antisense Nucleic Acid Drug Dev*, 7, 71-77.
13. Krieg, A.M., Matson, S. and Fisher, E. (1996) Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. *Antisense Nucleic Acid Drug Dev*, 6, 133-139.
14. Vaughn, J.P., Stekler, J., Demirdji, S., Mills, J.K., Caruthers, M.H., Iglehart, J.D. and Marks, J.R. (1996) Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. *Nucleic Acids Res*, 24, 4558-4564.
15. Marshall, W.S. and Caruthers, M.H. (1993) Phosphorodithioate DNA as a potential therapeutic drug. *Science*, 259, 1564-1570.
16. Ghosh, M.K., Ghosh, K., Dahl, O. and Cohen, J.S. (1993) Evaluation of some properties of a phosphorodithioate oligodeoxyribonucleotide for antisense application. *Nucleic Acids Res*, 21, 5761-5766.
17. Cho, Y., Zhu, F.C., Luxon, B.A. and Gorenstein, D.G. (1993) 2D 1H and 31P NMR spectra and distorted A-DNA-like duplex structure of a phosphorodithioate oligonucleotide. *J Biomol Struct Dyn*, 11, 685-702.
18. Sakatsume, O., Tanaka, H. and Takaku, H. (1992) Inhibitory effect of oligoribonucleotide phosphorodithioates against the 3'-exonuclease activity. *Nucleic Acids Symp Ser*, 195-196.
19. Marshall, W.S., Beaton, G., Stein, C.A., Matsukura, M. and Caruthers, M.H. (1992) Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine. *Proc Natl Acad Sci U S A*, 89, 6265-6269.